Therapeutic Response Statement (Sensitivity)

This therapeutic response statement Supports the relationship that PD-L1 (CPS) >= 1 status confers therapeutic sensitivity to Pembrolizumab in patients with Cervical Adenocarcinoma.

The Republic of Ireland's Health Service Executive (HSE) has approved pembrolizumab (200mg and 400mg) for reimbursement as a monotherapy treatment option for the maintenance treatment of adult patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 with a CPS >= 1 who have completed the induction chemotherapy component of treatment.

This statement is based on a regulatory approval from the Health Service Executive:

For the maintenance treatment of adult patients with persistent, recurrent, or metastatic cervical cancer whose tumours express PD-L1 with a CPS >= 1 who have completed the induction chemotherapy component of the treatment.

Citation

Pembrolizumab 200mg Monotherapy, 2026, version number 16, NCCP National SACT Regimen, NCCP, viewed 02/08/2026, https://healthservice.hse.ie/documents/6903/455_V15b__Pembrolizumab_200mg_Monotherapy.pdf

Contributions

Date	Contributor	Description
2026-08-01	Health Service Executive	Indication approved for reimbursement.
2024-01-16	Van Allen lab	Adding HSE approvals for reimbursement to database